Metastatic NSCLC - non-small cell lung cancer
Clinical trials for Metastatic NSCLC - non-small cell lung cancer explained in plain language.
Never miss a new study
Get alerted when new Metastatic NSCLC - non-small cell lung cancer trials appear
Sign up with your email to follow new studies for Metastatic NSCLC - non-small cell lung cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a targeted pill boost lung cancer treatment?
Disease control Recruiting nowThis phase 3 trial is investigating whether adding an investigational drug called zoldonrasib to standard first-line treatment (pembrolizumab plus chemotherapy) can help people with metastatic non-squamous non-small cell lung cancer that has a specific genetic mutation (RAS G12D)…
Matched conditions: METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER
Phase 3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Could a simple mineral improve lung cancer treatment?
Disease control Recruiting nowThis study tests whether adding magnesium to standard chemo-immunotherapy helps people with advanced non-small cell lung cancer. About 230 participants will receive either magnesium or a placebo, as both tablets and infusions. Neither patients nor doctors know who gets what. The …
Matched conditions: METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER
Phase 2/3 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Gentler chemo combo offers hope for elderly lung cancer patients
Disease control Recruiting nowThis study is for people aged 70 and older with advanced non-small cell lung cancer who are too frail for standard chemotherapy. It compares a lower-dose chemo plus an immunotherapy drug (cemiplimab) against immunotherapy alone. The goal is to find a treatment that works well but…
Matched conditions: METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER
Phase 2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for Hard-to-Treat lung cancer: targeted drug combo shows promise
Disease control Recruiting nowThis phase 2 trial is testing a combination of the targeted drug amivantamab plus chemotherapy (pemetrexed or gemcitabine) in 33 people with advanced non-small cell lung cancer that has a specific EGFR exon20 insertion mutation. Participants have not had prior treatment and are n…
Matched conditions: METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER
Phase 2 • Sponsor: Fondazione Ricerca Traslazionale • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Simple blood test may predict immunotherapy success in lung cancer
Knowledge-focused Recruiting nowThis study is looking at whether large granular lymphocytes (LGLs), a type of immune cell, can predict how well patients with advanced non-small cell lung cancer respond to the immunotherapy drug nivolumab. Researchers will measure LGL levels in 50 patients before and during trea…
Matched conditions: METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER
Sponsor: Necmettin Erbakan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC